Fierce Healthcare26d
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
The company expanded into weight loss in late 2023 with oral medication kits and added compounded GLP-1 medications to its offerings last May. Hims & Hers also offers subscriptions for Wegovy and ...
Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Barron's16d
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...
Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching End
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
NBC Washington26d
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers ... GLP-1 medications Ozempic and Wegovy. The company was a breakout star within the digital health sector in 2024, in part because of the success of its popular new weight loss ...
AOL25d
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...